Table 1 Baseline clinical and tumor features of all patients in CGGA

Age

 Mean age (range)

48.4 (17–81)

Gender (%)

 Male

192 (60.2%)

 Female

127 (39.8%)

Histology (%)

 AA

36 (11.3%)

 AO

17 (5.3%)

 AOA

58 (18.2%)

 GBM

208 (65.2%)

Grade (%)

 3

111 (34.8%)

 4

208 (65.2%)

TCGA subtype (%)

 Neural

11 (13.6%)

 Proneural

10 (12.3%)

 Classical

20 (24.7%)

 Mesenchymal

40 (49.4%)

IDH1/2 mutation (%)

 Yes

50 (20.2%)

 No

198 (79.8%)

MGMT promoter methylation (%)

 Yes

130 (50.8%)

 No

126 (49.2%)

EGFR amplification (%)

 Yes

14 (7.2%)

 No

180 (92.8%)

TP53 mutation (%)

 Yes

21 (18.7%)

 No

91 (81.3%)

LOH1p/19q (%)

 Yes

19 (9.8%)

 No

175 (90.2%)

Ki-67 expression (%)

 0–1

82 (47.7%)

 2–3

90 (52.3%)

Resection (%)

 Total

180 (62.0%)

 Subtotal

112 (48.0%)

Operation after progression

 Yes

36 (11.3%)

 No

283 (88.7%)

TMZ after progression

 Yes

23 (7.2%)

 No

296 (92.8%)

Therapy (%)

 Standard RT + TMZ

105 (33.3%)

 Unstandard

210 (66.7%)

Tumor involvement (%)

 Single lobe

181 (59.3%)

 Multi-lobes

124 (40.7%)